10x Genomics (TXG) Cash & Current Investments (2018 - 2025)
Historic Cash & Current Investments for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $523.4 million.
- 10x Genomics' Cash & Current Investments rose 3304.69% to $523.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $523.4 million, marking a year-over-year increase of 3304.69%. This contributed to the annual value of $523.4 million for FY2025, which is 3304.69% up from last year.
- According to the latest figures from Q4 2025, 10x Genomics' Cash & Current Investments is $523.4 million, which was up 3304.69% from $482.1 million recorded in Q3 2025.
- In the past 5 years, 10x Genomics' Cash & Current Investments registered a high of $640.1 million during Q2 2021, and its lowest value of $356.9 million during Q3 2023.
- For the 5-year period, 10x Genomics' Cash & Current Investments averaged around $468.2 million, with its median value being $438.6 million (2022).
- The largest annual percentage gain for 10x Genomics' Cash & Current Investments in the last 5 years was 7059.91% (2021), contrasted with its biggest fall of 2749.93% (2021).
- Quarter analysis of 5 years shows 10x Genomics' Cash & Current Investments stood at $588.5 million in 2021, then dropped by 26.93% to $430.0 million in 2022, then fell by 9.6% to $388.7 million in 2023, then grew by 1.21% to $393.4 million in 2024, then soared by 33.05% to $523.4 million in 2025.
- Its Cash & Current Investments stands at $523.4 million for Q4 2025, versus $482.1 million for Q3 2025 and $447.3 million for Q2 2025.